Delcath Systems (NASDAQ:DCTH) Releases Earnings Results, Beats Expectations By $0.19 EPS

Delcath Systems (NASDAQ:DCTH) announced its earnings results on Tuesday. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.19, RTT News reports. The company had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 1,007.65%. During the same quarter in the previous year, the business posted ($0.86) earnings per share.

Delcath Systems Stock Performance

Shares of NASDAQ DCTH opened at $5.09 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.30 and a quick ratio of 3.11. Delcath Systems has a 12 month low of $2.25 and a 12 month high of $7.99. The stock has a 50-day moving average price of $4.34 and a two-hundred day moving average price of $3.84.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DCTH. StockNews.com raised shares of Delcath Systems to a “sell” rating in a research report on Wednesday. HC Wainwright boosted their target price on shares of Delcath Systems from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, Delcath Systems has an average rating of “Moderate Buy” and an average target price of $18.50.

Insiders Place Their Bets

In other Delcath Systems news, Director Gil Aharon bought 26,882 shares of the stock in a transaction on Tuesday, March 19th. The stock was purchased at an average price of $3.72 per share, with a total value of $100,001.04. Following the completion of the purchase, the director now owns 1,069,710 shares in the company, valued at $3,979,321.20. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 21.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its stake in shares of Delcath Systems by 107.8% in the first quarter. Tower Research Capital LLC TRC now owns 4,663 shares of the company’s stock valued at $26,000 after buying an additional 2,419 shares during the period. Geode Capital Management LLC boosted its holdings in Delcath Systems by 4.8% in the first quarter. Geode Capital Management LLC now owns 62,733 shares of the company’s stock valued at $361,000 after acquiring an additional 2,851 shares during the last quarter. BlackRock Inc. boosted its holdings in Delcath Systems by 22.3% in the first quarter. BlackRock Inc. now owns 16,632 shares of the company’s stock valued at $96,000 after acquiring an additional 3,032 shares during the last quarter. Cibc World Market Inc. boosted its holdings in Delcath Systems by 4.0% in the first quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after acquiring an additional 3,432 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Delcath Systems by 77.7% in the second quarter. Renaissance Technologies LLC now owns 21,500 shares of the company’s stock valued at $125,000 after acquiring an additional 9,400 shares during the last quarter. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.